Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 3 | Journal of Inflammation

Fig. 3

From: Anti-inflammatory activity of non-selective PDE inhibitor aminophylline on the lung tissue and respiratory parameters in animal model of ARDS

Fig. 3

Levels of (A) a marker of oxidative modifications of proteins (expressed in nanomolar concentration of 3-nitrotyrosine, 3NT), (B) a marker of lipid oxidation (thiobarbituric acid-reactive substances, TBARS, expressed in micromolar concentration of malondialdehyde), and (C) total antioxidant capacity (TAC, expressed in micromolar concentration of copper reducing equivalents (CRE)) in the lung tissue of healthy ventilated animals (Control; n = 8), in animals with ARDS (ARDS; n = 8) and ARDS animals treated with aminophylline (ARDS/AMINO group; n = 8) after 4 h therapy. Data are presented as mean ± SD. Statistical comparisons: for ARDS vs. Control **p < 0.01, ***p < 0.001; for ARDS/AMINO vs. ARDS +p < 0.05, +++p < 0.001; ++++p < 0.0001

Back to article page